Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Is Cresco Labs Stock a Buy?

By Alex Carchidi - Dec 10, 2020 at 7:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This company could be on the verge of a boom, but it's given investors plenty of reasons to worry.

What's better than selling a copious amount of marijuana? Selling an even more copious amount of marijuana, more efficiently than before, and to an everwidening audience. Assuming you're a cannabis cultivation company, that is. 

Currently, marijuana wholesaler Cresco Labs ( CRLBF -1.94% ) is living the dream. But, despite its favorable growth trajectory, its appeal to investors may not be as sky-high as it is to its customers. Competition within the industry is rising, and Cresco still isn't listed on any U.S. stock exchange. Likewise, for all its strengths, it still hasn't proven that its business model is viable in the long term. Let's examine where the company is at right now to see if these issues should cause investors to steer clear.

A closeup of a marijuana flower.

Image source: Getty Images.

Why you should buy it

In my mind, there are several strong reasons to buy this stock. First, Cresco's quarterly revenue is growing explosively at a rate of 326.6% year over year. Growth like that could ebb over the next year and easily remain in the triple-digits.

It's growing so rapidly because it's already the largest cannabis wholesaler in the American market. The company derives 59% of its revenue from wholesale transactions, which is significantly more than its primary competitors like Curaleaf. As the rest of the industry expands market penetration in the form of retail locations, Cresco keeps pace by benefiting from economies of scale. Management is committed to maintaining its lead in wholesaling in the long term because that's where they think margins will be the highest. It's clear that the strategy is working -- so far.

Speaking of margins, management has also pushed forward with selling, general, and administrative (SG&A) cost cuts and other helpful improvements. In particular, its cultivation facilities in Illinois and Pennsylvania are becoming more efficient quite rapidly. Management credits the efficiency improvements at these facilities in particular for an improvement in operational gross profit as a percentage of revenue coming in at 53% in the quarter, compared to 47% in the previous quarter.  

Most importantly, thanks to falling costs and rising revenue, the company's most recent adjusted earnings before interest, taxes, amortization, and depreciation (EBITDA) of $46.4 million are the largest it has ever reported. Its $17.8 million in cash flow from operations is also a company record.

Why it might be better to wait

Even though its core financial metrics are improving rapidly, Cresco is still unprofitable, with a negative profit margin of 17.88%. But compared to companies like Aurora Cannabis, it's much closer to consistently profitable operations. Unfortunately, management hasn't provided any explicit estimates for when profitability might occur. My estimate, based on the last few quarters of data, is that it might be profitable by the end of 2021, which is a bit far in the future for conservative investors looking to make a decision today. 

Furthermore, Cresco competes in the medicinal and recreational cannabis markets, but its portfolio of adult use brands is far larger than its medicinal holdings. As the marijuana industry experiences rising business competition from a wave of legalization in the U.S., it may not be able to defend its medicinal market share against others as a result. This is especially concerning because it enjoys a higher price point with its Remedi medicinal brand in comparison to its adult-use brands like Good News and its newest brand, High Supply. If the price is right for medicinal cannabis, why does management continue to advance with lower-price and less-differentiated brands?

The verdict

That last question isn't a dealbreaker for me. The overall strategy -- wholesaling and focusing on the recreational market -- appears to be working. Management has shown that it is effective at lowering costs, increasing sales revenue, and scaling production capacity keenly with demand. As far as cannabis stocks go, Cresco is a winner, even if it hasn't proven that its operations are sustainable in the long run yet. I'd be comfortable with buying this stock today, and I expect that waiting a year would make the decision even easier.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
CRLBF
$8.09 (-1.94%) $0.16
Aurora Cannabis Stock Quote
Aurora Cannabis
ACB
$5.82 (-5.21%) $0.32
Curaleaf Holdings, Inc. Stock Quote
Curaleaf Holdings, Inc.
CURLF
$9.23 (-0.65%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.